Characterization of Gene Mutations and Its Association with Prognosis of KRAS,NRAS,BRAF,and PIK3CA in Different Colorectal Cancer Metastatic Sites
10.11969/j.issn.1673-548X.2025.01.010
- VernacularTitle:结直肠癌不同转移部位的KRAS、NRAS、BRAF、PIK3CA基因突变特点及其与预后的关系
- Author:
Nan YANG
1
;
Le HE
;
Zhenjun LI
Author Information
1. 730000 兰州,甘肃中医药大学第一临床医学院
- Publication Type:Journal Article
- Keywords:
Colorectal cancer;
Metastasis;
KRAS;
NRAS;
BRAF;
PIK3CA
- From:
Journal of Medical Research
2025;54(1):48-53,115
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the characteristics of KRAS,NRAS,BRAF,and PIK3CA mutations in different colorectal cancer(CRC)metastatic sites and their correlation with prognosis.Methods The mutations of KRAS,NRAS,BRAF,and PIK3CA were detected in 205 cases by using a mutation amplification refractory mutation system(ARMS),and their correlation with clinical fea-tures,metastatic sites,and related prognosis was analyzed.Results The mutation rates of KRAS,NRAS,BRAF,and PIK3CA were 57.1％,4.4％,4.4％and 3.9％,respectively.Mutations of KRAS are increased in women,patients with colorectal cancer,and patients with stage Ⅲ-Ⅳ colorectal cancer.The BRAF mutation rate in right-sided colon cancer was increased(P＜0.05).KRAS mutations were com-monly seen during pulmonary metastasis,while NRAS mutation rates were higher during liver metastasis,and the proportion of peritoneal metastases was higher when BRAF mutated.KRAS and NRAS mutations were identified as elevated risks for lung and liver metastasis in colorectal cancer(CRC)(P＜0.01).BRAF mutation types lead to shorter overall survival(OS)in CRC cases with liver and peritoneal metastasis,whereas KRAS mutations indicate poorer prognosis in lung metastasis.Both KRAS and BRAF mutations are independent prog-nostic indicators of unfavorable outcomes in CRC with lung and liver metastasis,respectively(P＜0.01).Conclusion KRAS,NRAS and BRAF mutations are closely associated with distant metastasis and prognosis in CRC.Clinical practice should routinely assess these mutations to provide critical guidance for treatment decisions.
